Association Between Serum Irisin Levels and ST-Segment Elevation Myocardial Infarction.

Area of Science:

• Cardiology
• Biochemistry
• Biomarkers

Background:

• ST-elevation myocardial infarction (STEMI) is a critical cardiovascular condition with significant morbidity and mortality risks.
• Irisin, an adipomyokine, is linked to various health conditions, with elevated levels post-STEMI associated with adverse cardiovascular events.

Purpose of the Study:

• To investigate the association between serum irisin levels and acute myocardial infarction (AMI).
• To determine if irisin can serve as a biomarker for AMI severity in STEMI patients.
• To explore correlations between serum irisin and cardiac troponin-I (cTi) levels.

Main Methods:

• The study included 90 participants: 46 controls and 44 STEMI patients.
• Evaluated demographic data, medical history (diabetes, hypertension), ECG findings, blood biochemistry, cardiac biomarkers (cTi), and serum irisin levels.

Main Results:

• STEMI patients exhibited significantly lower heart rate and higher ST-elevation and QTc intervals compared to controls (p < 0.05).
• Serum irisin levels were significantly lower in STEMI patients (p < 0.001).
• Decreased irisin levels correlated with increased cTi and QTc (p < 0.05), with 93% sensitivity and 78% specificity.

Conclusions:

• Reduced irisin levels are highly predictive of STEMI.
• Serum irisin levels in STEMI patients are associated with cTi and QTc intervals.
• Irisin shows promise as a biomarker for assessing acute myocardial infarction severity.